阿尔茨海默氏症的疾病是阿尔茨海默氏症
Clive Ballard1, Serge Gauthier, Anne Corbett
1Wolfson Centre for Age-Related Diseases, King's College London, London, UK. clive.ballard@kcl.ac.uk
Lancet (London, England)
|March 5, 2011
概括
阿尔茨海默病影响全球数百万人,需要更好地了解其原因,诊断和危险因素. 这篇概述强调了最近的证据,并讨论了降低风险的潜在策略.
科学领域:
- 神经学 神经学
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,全球约有2400万人受到影响.
- 阿尔茨海默病构成了重大的公共卫生挑战,强调了它作为研究优先事项的地位.
- 目前的治疗方法可以控制阿尔茨海默氏症的症状,但疾病修饰疗法需要对病变发生的更深入的理解.
研究的目的:
- 为提供关于阿尔茨海默病 (AD) 的最新证据的概述.
- 讨论AD的流行病学,发病,诊断和治疗.
- 探索潜在的阿尔茨海默病和认知衰退风险降低策略.
主要方法:
- 对最近证据的文献综述.
- 综合当前对阿尔茨海默病变的理解.
- 分析诊断方面的进展,包括生物标志物和神经成像.
- 检查已识别的阿尔茨海默病和痴呆症的风险和保护因素.
主要成果:
- 在了解AD风险和防护因素方面取得了重大进展.
- 诊断方法的持续发展,需要生物标志物共识.
- 有证据表明,干预措施有可能降低AD风险.
- 获得许可的治疗方法提供症状缓解,但不能改变疾病.
结论:
- 进一步的研究对于开发阿尔茨海默病修饰疾病的治疗方法至关重要.
- 需要增强的诊断工具,包括经过验证的生物标志物面板.
- 了解和减轻风险因素是减轻阿尔茨海默病和痴呆症负担的关键.
相关概念视频
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

